Implantica Submits Final Response to FDA for RefluxStop® Approval
Implantica AG has submitted its final response to the FDA regarding the PMA application for its RefluxStop® device, aimed at treating acid reflux. This submission includes answers to FDA queries and results from additional testing requested after previous inspections. The RefluxStop® device is designed to improve GERD treatment while maintaining the body’s natural anatomy, and its PMA application is backed by extensive clinical data.
VADUZ, Liechtenstein, May 20, 2026 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers,…